Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

57 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Optimization of rituximab for the treatment of DLBCL: increasing the dose for elderly male patients.
Pfreundschuh M, Murawski N, Zeynalova S, Ziepert M, Loeffler M, Hänel M, Dierlamm J, Keller U, Dreyling M, Truemper L, Frickhofen N, Hünerlitürkoglu AN, Schmitz N, Pöschel V, Rixecker T, Berdel C, Rübe C, Held G, Zwick C. Pfreundschuh M, et al. Among authors: zwick c. Br J Haematol. 2017 Nov;179(3):410-420. doi: 10.1111/bjh.14860. Epub 2017 Oct 8. Br J Haematol. 2017. PMID: 28990173 Free article. Clinical Trial.
Unresolved issues in diffuse large B-cell lymphomas.
Murawski N, Zwick C, Pfreundschuh M. Murawski N, et al. Among authors: zwick c. Expert Rev Anticancer Ther. 2010 Mar;10(3):387-402. doi: 10.1586/era.09.170. Expert Rev Anticancer Ther. 2010. PMID: 20214520 Review.
Rituximab in high-grade lymphoma.
Zwick C, Murawski N, Pfreundschuh M; German High-Grade Non-Hodgkin Lymphoma Study Group. Zwick C, et al. Semin Hematol. 2010 Apr;47(2):148-55. doi: 10.1053/j.seminhematol.2010.01.008. Semin Hematol. 2010. PMID: 20350662 Review.
The role of sex and weight on rituximab clearance and serum elimination half-life in elderly patients with DLBCL.
Müller C, Murawski N, Wiesen MH, Held G, Poeschel V, Zeynalova S, Wenger M, Nickenig C, Peter N, Lengfelder E, Metzner B, Rixecker T, Zwick C, Pfreundschuh M, Reiser M. Müller C, et al. Among authors: zwick c. Blood. 2012 Apr 5;119(14):3276-84. doi: 10.1182/blood-2011-09-380949. Epub 2012 Feb 15. Blood. 2012. PMID: 22337718 Free article. Clinical Trial.
Suboptimal dosing of rituximab in male and female patients with DLBCL.
Pfreundschuh M, Müller C, Zeynalova S, Kuhnt E, Wiesen MH, Held G, Rixecker T, Poeschel V, Zwick C, Reiser M, Schmitz N, Murawski N. Pfreundschuh M, et al. Among authors: zwick c. Blood. 2014 Jan 30;123(5):640-6. doi: 10.1182/blood-2013-07-517037. Epub 2013 Dec 2. Blood. 2014. PMID: 24297867 Free article. Clinical Trial.
Role of radiotherapy to bulky disease in elderly patients with aggressive B-cell lymphoma.
Held G, Murawski N, Ziepert M, Fleckenstein J, Pöschel V, Zwick C, Bittenbring J, Hänel M, Wilhelm S, Schubert J, Schmitz N, Löffler M, Rübe C, Pfreundschuh M. Held G, et al. Among authors: zwick c. J Clin Oncol. 2014 Apr 10;32(11):1112-8. doi: 10.1200/JCO.2013.51.4505. Epub 2014 Feb 3. J Clin Oncol. 2014. PMID: 24493716 Clinical Trial.
Optimization of rituximab for the treatment of diffuse large B-cell lymphoma (II): extended rituximab exposure time in the SMARTE-R-CHOP-14 trial of the german high-grade non-Hodgkin lymphoma study group.
Pfreundschuh M, Poeschel V, Zeynalova S, Hänel M, Held G, Schmitz N, Viardot A, Dreyling MH, Hallek M, Mueller C, Wiesen MH, Witzens-Harig M, Truemper L, Keller U, Rixecker T, Zwick C, Murawski N. Pfreundschuh M, et al. Among authors: zwick c. J Clin Oncol. 2014 Dec 20;32(36):4127-33. doi: 10.1200/JCO.2013.54.6861. Epub 2014 Nov 17. J Clin Oncol. 2014. PMID: 25403207 Clinical Trial.
Optimization of rituximab for the treatment of DLBCL (I): dose-dense rituximab in the DENSE-R-CHOP-14 trial of the DSHNHL.
Murawski N, Pfreundschuh M, Zeynalova S, Poeschel V, Hänel M, Held G, Schmitz N, Viardot A, Schmidt C, Hallek M, Witzens-Harig M, Trümper L, Rixecker T, Zwick C. Murawski N, et al. Among authors: zwick c. Ann Oncol. 2014 Sep;25(9):1800-1806. doi: 10.1093/annonc/mdu208. Epub 2014 Jun 13. Ann Oncol. 2014. PMID: 24928834 Free article. Clinical Trial.
Equitoxicity of bolus and infusional etoposide: results of a multicenter randomised trial of the German High-Grade Non-Hodgkins Lymphoma Study Group (DSHNHL) in elderly patients with refractory or relapsing aggressive non-Hodgkin lymphoma using the CEMP regimen (cisplatinum, etoposide, mitoxantrone and prednisone).
Zwick C, Birkmann J, Peter N, Bodenstein H, Fuchs R, Hänel M, Reiser M, Hensel M, Clemens M, Zeynalova S, Ziepert M, Pfreundschuh M; German High-Grade Non-Hodgkins Lymphoma Study Group (DSHNHL). Zwick C, et al. Ann Hematol. 2008 Sep;87(9):717-26. doi: 10.1007/s00277-008-0500-1. Epub 2008 Jun 28. Ann Hematol. 2008. PMID: 18587579 Clinical Trial.
57 results